Ratings Alpine Immune Sciences, Inc.

Equities

ALPN

US02083G1004

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
64.96 ^USD	-0.02%		+0.22%	+240.82%

May. 10	Alpine Immune Sciences, Vertex Pharmaceuticals Deal Crosses Another Milestone	MT
May. 09	Alpine Immune Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental situation
According to Refinitiv, the company's ESG score for its industry is poor.

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
The company's "enterprise value to sales" ratio is among the highest in the world.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
ALPINE IMMUNE SCIENCES, INC.	+240.82%	4.46B	C-
VERTEX PHARMACEUTICALS INCORPORATED	+8.29%	113B	B+
REGENERON PHARMACEUTICALS, INC.	+10.21%	106B	B+
ARGENX SE	+0.41%	22.27B	B
BIONTECH SE	-11.90%	22.22B	B+
GENMAB A/S	-5.99%	19.43B	A-
WUXI APPTEC CO., LTD.	-37.36%	17.87B	A-
BEIGENE, LTD.	-5.17%	17.24B	B
NEUROCRINE BIOSCIENCES, INC.	+7.70%	14.29B	C+
SAREPTA THERAPEUTICS, INC.	+37.65%	12.52B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes